CERo Therapeutics Aktie - CERO

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Current Price

0,91

Gebot

0,91

Fragen

0,96

Volumen

61.983

0,90 Tagesbereich 0,9412

0,82 52-Wochen-Bereich 376,00

Handelsende

0,96

Handelsbeginn

0,94

Letzte Trade

100

0.91

(formt)

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

23.344.178

Finanzvolumen

US$ 57.597

VWAP

0,929237

CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services

Company continues to improve its market position as it nears launch of its Phase 1 clinical trial in AML SOUTH...

CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting

SOUTH SAN FRANSCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq:...

CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays

Company continues toward the initiation of its Phase 1 Clinical Trial in AML for CER-1236 SOUTH SAN FRANSCISCO...

CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14

New poster to highlight preclinical data of CER-1236 in ovarian cancer SOUTH SAN FRANSCISCO, Calif., March...

CERo Therapeutics Holdings, Inc. Highlights Progress

Increased cash balance and momentum with both Nasdaq and Phase 1 trial initiation mark strong beginning for...

CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

SOUTH SAN FRANSCISCO, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq:...

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split

SOUTH SAN FRANSCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq:...

CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO

SOUTH SAN FRANCISCO, Calif, Dec. 06, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq:...

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

SOUTH SAN FRANCISCO, Calif, Nov. 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq:...

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

Data presented as part of a poster at the SITC 2024 Conference SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.04	-4.21052631579	0.95	1.03	0.82	176438	0.95623469	CS
4	-1.04	-53.3333333333	1.95	1.984	0.82	448882	1.10206651	CS
12	-5.25	-85.2272727273	6.16	10.25	0.82	23344178	5.24384216	CS
26	-12.08	-92.9946112394	12.99	44.77	0.82	48363180	17.17502966	CS
52	-205.09	-99.5582524272	206	376	0.82	25869703	18.77328322	CS
156	-524.09	-99.8266666667	525	1238	0.82	23717647	20.40126244	CS
260	-524.09	-99.8266666667	525	1238	0.82	23717647	20.40126244	CS

CERO - Frequently Asked Questions (FAQ)

What is the current CERo Therapeutics share price?

The current share price of CERo Therapeutics is US$ 0,91

What is the 1 year trading range for CERo Therapeutics share price?

CERo Therapeutics has traded in the range of US$ 0,82 to US$ 376,00 during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
SGLYSingularity Future Technology Ltd	US$ 1,6799 (143,43%)	30,76M
WINVWinVest Acquisition Corporation	US$ 25,00 (107,30%)	463
VVPRVivoPower International PLC	US$ 1,2899 (52,13%)	65,08M
RNAZTransCode Therapeutics Inc	US$ 1,12 (45,45%)	216,22M
GLTOGalecto Inc	US$ 6,00 (44,93%)	10,71M
YHCLQR House Inc	US$ 0,40 (-82,38%)	38,3M
KZIAKazia Therapeutics Ltd	US$ 0,9759 (-80,02%)	53,87k
DMNDamon Inc	US$ 0,0373 (-70,02%)	301,97M
TCBPTC BioPharm Holdings PLC	US$ 0,5046 (-67,23%)	5,89M
SOWGSow Good Inc	US$ 1,53 (-44,36%)	673,92k
DMNDamon Inc	US$ 0,0373 (-70,02%)	304,17M
NVDANVIDIA Corporation	US$ 117,70 (-0,70%)	264,42M
RNAZTransCode Therapeutics Inc	US$ 1,12 (45,45%)	216,22M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 9,03 (10,66%)	175,77M
HOLOMicroCloud Hologram Inc	US$ 1,00 (32,36%)	141,98M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

CERo Therapeutics Holdings Inc (CERO)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

CERO Neueste Nachrichten

CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services

CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting

CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays

CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14

CERo Therapeutics Holdings, Inc. Highlights Progress

CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split

CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services

CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting

CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays

CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14

CERo Therapeutics Holdings, Inc. Highlights Progress

CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split

CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO

CERO - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

CERo Therapeutics Holdings Inc (CERO) Börsenkurse

CERo Therapeutics Holdings Inc (CERO)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

CERO Neueste Nachrichten

CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services

CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting

CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays

CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14

CERo Therapeutics Holdings, Inc. Highlights Progress

CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split

CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services

CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting

CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays

CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14

CERo Therapeutics Holdings, Inc. Highlights Progress

CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split

CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO

CERO - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen